A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 222 participants.

Also called NCT07222917

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 222 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07222917
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Bulgaria, Canada, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07222917. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-05 (actual); primary completion 2026-12-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Acronym
BaxDuo-Baltic
Condition
Chronic Kidney Disease and Hypertension
Intervention (Drug)
Baxdrostat/dapagliflozin
Intervention (Drug)
Baxdrostat/Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07222917
Content hash
5663bae52b82c87a733bd0c06adeca0b1db7a2aab11a071465a91a89fba5f8af